{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-016231","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2023-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.664424+00:00","generated_at":"2026-06-20T09:00:04.050295+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ResMed Q2 revenue up 16% to $1.03B, EPS $1.53; CEO Farrell appointed Board Chair","bullets":["Revenue $1,033.7M (+16% YoY, +20% constant currency); GAAP EPS $1.53, non-GAAP $1.66.","Gross margin contracted 30 bps to 56.1%; non-GAAP gross margin 56.8%.","Mick Farrell, current CEO, named Board Chair; founder Peter Farrell becomes Chair Emeritus.","Quarterly dividend $0.44/share declared, payable March 16, record date Feb 9.","Closed acquisition of MEDIFOX DAN in Germany, expanding out-of-hospital SaaS business."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-016231","json":"https://secwatch.observer/filing/0001193125-23-016231.json","markdown":"https://secwatch.observer/filing/0001193125-23-016231.md","text":"https://secwatch.observer/filing/0001193125-23-016231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/0001193125-23-016231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/d369496d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T09:00:04.050295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d94c0f16fffd8093e36cc7e489ea1aba0b54c2de","claim":"RESMED INC reported the quarter ended December 31, 2022 results: revenue $ 1,033.7, net income $ 224.9, EPS $ 1.53.","evidence_excerpt":"Three Months Ended December 31, 2022 December 31, 2021 % Change Constant Currency (A) Revenue $ 1,033.7 $ 894.9 16 % 20 % Gross margin 56.1 % 56.4 % (1 ) Non-GAAP gross margin (B) 56.8 % 57.6 % (1 ) Selling, general, and administrative expenses 211.7 185.4 14 20 Research and development expenses 69.9 62.5 12 15 Income from operations 280.2 248.7 13 Non-GAAP income from operations (B) 305.5 267.7 14 Net income 224.9 201.8 11 Non-GAAP net income (B) 244.4 216.2 13 Diluted earnings per share $ 1.53 $ 1.37 12 Non-GAAP diluted earnings per share (B) $ 1.66 $ 1.47 13","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/0001193125-23-016231-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$ 1,033.7"},{"label":"Net income","value":"$ 224.9"},{"label":"EPS","value":"$ 1.53"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9021a49663","claim":"Michael J. 'Mick' Farrell was appointed as chair of the board of directors at RESMED INC.","evidence_excerpt":"On January 25, 2023, our board of directors appointed Michael J. “Mick” Farrell as chair of our board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/0001193125-23-016231-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"chair of the board of directors"}],"fact_type":"executive_change"},{"claim_id":"fa5f40e1b2","claim":"Dr. Peter C. Farrell was appointed as chair emeritus at RESMED INC.","evidence_excerpt":"In recognition of Dr. Farrell’s long and valuable service as chair, the board of directors appointed him to the new director position of chair emeritus, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/0001193125-23-016231-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"chair emeritus"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}